{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:38:50Z","timestamp":1793662730701,"version":"4.5.1"},"reference-count":208,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Morphea, also known as localized scleroderma, is a chronic inflammatory connective tissue disorder with variable clinical presentations, that affects both adults and children. It is characterized by inflammation and fibrosis of the skin and underlying soft tissue, in certain cases even of the surrounding structures such as fascia, muscle, bone and central nervous system. While the etiology is still unknown, many factors may contribute to disease development, including genetic predisposition, vascular dysregulation, T<jats:sub>H<\/jats:sub>1\/T<jats:sub>H<\/jats:sub>2 imbalance with chemokines and cytokines associated with interferon-\u03b3 and profibrotic pathways as well as certain environmental factors. Since the disease may progress to permanent cosmetic and functional sequelae, it is crucial to properly assess the disease activity and to initiate promptly the adequate treatment, thus preventing subsequent damage. The mainstay of treatment is based on corticosteroids and methotrexate. These, however, are limited by their toxicity, especially if applied long-term. Furthermore, corticosteroids and methotrexate often do not sufficiently control the disease and\/or the frequent relapses of morphea. This review presents the current understanding of morphea by discussing its epidemiology, diagnosis, management and prognosis. In addition, it will describe recent pathogenetic findings, thus proposing potential novel targets for therapeutic development in morphea.<\/jats:p>","DOI":"10.3389\/fmed.2023.1108623","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T05:04:47Z","timestamp":1676264687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":135,"title":["Morphea: The 2023 update"],"prefix":"10.3389","volume":"10","author":[{"given":"Cristian","family":"Papara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Vorobyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","article-title":"Feitosa de Oliveira SK, Punaro MG, et al. juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study","volume":"45","author":"Zulian","year":"2006","journal-title":"Rheumatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","article-title":"Distinct autoimmune syndromes in Morphea","volume":"145","author":"Leitenberger","year":"2009","journal-title":"Arch Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/rheumatology\/27.4.286","article-title":"An epidemiological study of scleroderma in the west midlands","volume":"27","author":"Silman","year":"1988","journal-title":"Rheumatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2009.07178.x","article-title":"Diagnosis and therapy of localized scleroderma","volume":"7","author":"Kreuter","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaad.2010.05.045","article-title":"Update on morphea","volume":"64","author":"Fett","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/art.21264","article-title":"Localized scleroderma in childhood is not just a skin disease","volume":"52","author":"Zulian","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/art.1780370218","article-title":"Immunocytochemical localization and serologic detection of transforming growth factor \u03b21","volume":"37","author":"Higley","year":"1994","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF01262331","article-title":"Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma","volume":"287","author":"Ihn","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000094242","article-title":"Chemokines and chemokine receptors in scleroderma","volume":"140","author":"Yamamoto","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","article-title":"Immunopathogenesis of pediatric localized scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jaad.2010.05.046","article-title":"Update on morphea","volume":"64","author":"Fett","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjd.13514","article-title":"Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease","volume":"172","author":"Mertens","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/archdermatol.2010.239","article-title":"An evaluation of Long-term outcomes in adults with pediatric-onset Morphea","volume":"146","author":"Saxton-Daniels","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2020.0034","article-title":"Changes in disease activity and damage over time in patients with Morphea","volume":"156","author":"O\u2019Brien","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/bjd.17312","article-title":"Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma","volume":"180","author":"Kurzinski","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology Centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"ref18","first-page":"73","article-title":"The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993","volume":"24","author":"Peterson","year":"1997","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0889-857X(02)00010-8","article-title":"Scleroderma in children and adolescents","volume":"28","author":"Murray","year":"2002","journal-title":"Rheum Dis Clin N Am"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1365-2133.2011.10600.x","article-title":"Misdiagnosis and delay in referral of children with localized scleroderma","volume":"165","author":"Weibel","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/acr.20070","article-title":"Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland","volume":"62","author":"Herrick","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin N Am"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco","year":"2019","journal-title":"Clin Epidemiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamadermatol.2013.4207","article-title":"Morphea in adults and children cohort III: nested case-control study\u2013the clinical significance of autoantibodies in morphea","volume":"149","author":"Dharamsi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaad.2008.05.005","article-title":"Pediatric morphea (localized scleroderma): review of 136 patients","volume":"59","author":"Christen-Zaech","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"ref26","first-page":"171","article-title":"Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases","volume":"13","author":"Marzano","year":"2003","journal-title":"Eur J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jpeds.2006.04.052","article-title":"Congenital localized scleroderma","volume":"149","author":"Zulian","year":"2006","journal-title":"J Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/pde.13605","article-title":"Natural history and extracutaneous involvement of congenital morphea: multicenter retrospective cohort study and literature review","volume":"35","author":"Mansour","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-92616-8_7","article-title":"Immunogenetics of morphea and lichen sclerosus","volume":"1367","author":"Khan Mohammad Beigi","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1002\/art.38814","article-title":"Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against Morphea: findings from the Morphea in adults and children cohort","volume":"66","author":"Jacobe","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1399-0039.1989.tb01739.x","article-title":"Association of HLA antigens with progressive systemic sclerosis and morphea","volume":"34","author":"K\u00fchnl","year":"1989","journal-title":"Tissue Antigens"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3389\/fimmu.2019.01487","article-title":"Autoantibodies in Morphea: an update","volume":"10","author":"Khatri","year":"2019","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/rheumatology\/keh487","article-title":"Localized scleroderma is an autoimmune disorder","volume":"44","author":"Takehara","year":"2005","journal-title":"Rheumatology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaad.2019.02.039","article-title":"Radiation-induced morphea: association with autoimmune comorbidities, severity, and response to therapy","volume":"81","author":"Mittal","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0961203311429551","article-title":"Autoimmune syndrome induced by adjuvants (ASIA) in the Middle East: morphea following silicone implantation","volume":"21","author":"Kivity","year":"2012","journal-title":"Lupus"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1684\/ejd.2014.2303","article-title":"Morphea as a sign of autoimmune syndrome induced by adjuvants (ASIA)","volume":"24","author":"Frances","year":"2014","journal-title":"Eur J Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ijd.16062","article-title":"A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins","volume":"61","author":"Metin","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1111\/ijd.16156","article-title":"Morphea and COVID-19 mRNA vaccine","volume":"61","author":"Sookaromdee","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1111\/jdv.18249","article-title":"Generalized morphea after COVID-19 vaccines: a case series","volume":"36","author":"Paolino","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e15709","DOI":"10.1111\/dth.15709","article-title":"Generalized morphea following the COVID vaccine: a series of two patients and a bibliographic review","volume":"35","author":"Anto\u00f1anzas","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ken405","article-title":"Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis","volume":"48","author":"Badea","year":"2008","journal-title":"Rheumatology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/art.1780200410","article-title":"Cellular infiltrates in scleroderma skin","volume":"20","author":"Fleischmajer","year":"1977","journal-title":"Arthritis Rheum"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jaad.2016.12.020","article-title":"Histopathological changes in morphea and their clinical correlates: results from the Morphea in adults and children cohort V","volume":"76","author":"Walker","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jid.2018.09.025","article-title":"Identifying the signature immune phenotypes present in pediatric localized scleroderma","volume":"139","author":"Mirizio","year":"2019","journal-title":"J Investig Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"669116","DOI":"10.3389\/fped.2021.669116","article-title":"Genetic signatures from RNA sequencing of pediatric localized scleroderma skin","volume":"9","author":"Mirizio","year":"2021","journal-title":"Front Pediatr"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/cup.12947","article-title":"Th1- and Th17-polarized immune infiltrates in eosinophilic fasciitis-a potential marker for histopathologic distinction from morphea","volume":"44","author":"Moy","year":"2017","journal-title":"J Cutan Pathol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cyto.2011.04.001","article-title":"Cytokine profiles in localized scleroderma and relationship to clinical features","volume":"55","author":"Kurzinski","year":"2011","journal-title":"Cytokine"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.3390\/jcm11216375","article-title":"Serum levels of selected IL-1 family cytokines in patients with Morphea","volume":"11","author":"Szczepanik-Ku\u0142ak","year":"2022","journal-title":"J Clin Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10067-017-3580-2","article-title":"Multiplex assessment of serum cytokine and chemokine levels in idiopathic morphea and vitamin K1-induced morphea","volume":"36","author":"Cox","year":"2017","journal-title":"Clin Rheumatol"},{"key":"ref52","first-page":"823","article-title":"Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents","volume":"37","author":"Fertin","year":"1991","journal-title":"Cell Mol Biol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1111\/jdv.17834","article-title":"Early involvement of lymphatic vessels in pathophysiology of morphea","volume":"36","author":"Monfort","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0190-9622(00)90010-0","article-title":"Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma","volume":"42","author":"Yamane","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/jdv.15120","article-title":"CD34 stromal expression is inversely proportional to smooth muscle actin expression and extent of morphea","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","article-title":"Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment","volume":"10","author":"Harjunp\u00e4\u00e4","year":"2019","journal-title":"Front Immunol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/157488807781696249","article-title":"CD34+ Fibrocytes: morphology, Histogenesis and function","volume":"2","author":"Barth","year":"2007","journal-title":"Curr Stem Cell Res Ther"},{"key":"ref58","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-14729-1","volume-title":"Practical Skin Pathology","author":"Mutasim","year":"2015"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1172\/JCI111480","article-title":"Selective inhibition of human diploid fibroblast collagen synthesis by interferons","volume":"74","author":"Jimenez","year":"1984","journal-title":"J Clin Investig"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5114\/ceji.2015.50841","article-title":"The role of dendritic cells and regulatory T cells in the pathogenesis of morphea","volume":"1","author":"Osmola-Ma\u0144kowska","year":"2015","journal-title":"Central Eur J Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/ddg.12724","article-title":"German guidelines for the diagnosis and therapy of localized scleroderma","volume":"14","author":"Kreuter","year":"2016","journal-title":"JDDG"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4065\/70.11.1068","article-title":"Classification of morphea (localized scleroderma)","volume":"70","author":"Peterson","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"208","DOI":"10.23736\/S0392-0488.18.05922-9","article-title":"Scleroderma with an update about clinico-pathological correlation","volume":"153","author":"Rongioletti","year":"2018","journal-title":"Italian J Dermatol Venereol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"An Bras Dermatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0001-7310(08)74962-7","article-title":"Patient with generalized guttate morphea and lichen sclerosus et atrophicus","volume":"99","author":"Blaya","year":"2008","journal-title":"Actas Dermosifiliogr"},{"key":"ref67","volume-title":"Atrophoderma of Pasini and Pierini","author":"Litaiem","year":"2022"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/120347540300700104","article-title":"Keloid Morphea and nodular scleroderma: two distinct clinical variants of scleroderma?","volume":"7","author":"Rencic","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/DAD.0000000000001629","article-title":"Morphea with Keloidal features: a case report and review of the literature","volume":"42","author":"Yu","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0190-9622(94)70113-X","article-title":"Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases","volume":"30","author":"Daoud","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5070\/D33R74N91Z","article-title":"Bullous morphea","volume":"8","author":"Gallagher","year":"2002","journal-title":"Dermatol Online J"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/00000372-199408000-00011","article-title":"Bullous Morphea","volume":"16","author":"Trattner","year":"1994","journal-title":"Am J Dermatopathol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2016.08.052","article-title":"Skin mapping for the classification of generalized morphea","volume":"78","author":"Teske","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ad.2019.05.021","article-title":"FR-Morfea generalizada: definici\u00f3n y asociaciones","volume":"112","author":"Garc\u00eda-V\u00e1zquez","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.jaad.2004.10.881","article-title":"Disabling pansclerotic morphea: clinical presentation in two adults","volume":"53","author":"Maragh","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3899\/jrheum.130029","article-title":"Clinical features of patients with Morphea and the Pansclerotic subtype: a cross-sectional study from the Morphea in adults and children cohort","volume":"41","author":"Kim","year":"2014","journal-title":"J Rheumatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"bcr-2017-222132","DOI":"10.1136\/bcr-2017-222132","article-title":"Disabling pansclerotic morphoea of childhood","volume":"17","author":"Jamalpur","year":"2018","journal-title":"BMJ Case Rep"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40257-017-0269-x","article-title":"Morphea and eosinophilic fasciitis: an update","volume":"18","author":"Mertens","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1007\/s10067-022-06311-y","article-title":"The groove sign in eosinophilic fasciitis","volume":"41","author":"Camard","year":"2022","journal-title":"Clin Rheumatol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/ker366","article-title":"Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients","volume":"51","author":"Lebeaux","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2133.2008.08647.x","article-title":"Linear morphoea follows Blaschko\u2019s lines","volume":"159","author":"Weibel","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1440-0960.1992.tb00107.x","article-title":"Linear scleroderma with severe leg deformity","volume":"33","author":"Hatzis","year":"1992","journal-title":"Australas J Dermatol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"719685","DOI":"10.1155\/2012\/719685","article-title":"Neurologic involvement in scleroderma en coup de sabre","volume":"2012","author":"Amaral","year":"2012","journal-title":"Autoimmune Dis"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1007\/s10067-020-05289-9","article-title":"En coup de sabre presenting as status epilepticus","volume":"39","author":"Kashyape","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1542\/peds.2005-0470","article-title":"Linear scleroderma en coup de sabre with associated neurologic abnormalities","volume":"117","author":"Holland","year":"2006","journal-title":"Pediatrics"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jaad.2006.10.959","article-title":"En coup de sabre morphea and parry-Romberg syndrome: a retrospective review of 54 patients","volume":"56","author":"Tollefson","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-015-0250-9","article-title":"Progressive hemifacial atrophy: a review","volume":"10","author":"Tolkachjov","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1046\/j.1468-3083.2002.00442.x","article-title":"Scleroderma \u201cen coup de sabre\u201d and progressive facial hemiatrophy. Is it possible to differentiate them?","volume":"16","author":"Orozco-Covarrubias","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/00207454.2016.1244823","article-title":"Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course","volume":"127","author":"Lis-\u015awi\u0119ty","year":"2017","journal-title":"Int J Neurosci"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2230.2004.01422.x","article-title":"Does solitary morphoea profunda progress?","volume":"29","author":"Azad","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000141959","article-title":"Primary atrophic solitary morphea profunda","volume":"217","author":"Khelifa","year":"2008","journal-title":"Dermatology"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jdcr.2022.02.033","article-title":"A case of generalized morphea profunda following SARS-CoV-2 infection","volume":"23","author":"Stephens","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref93","first-page":"32","article-title":"Solitary morphea profunda following trauma sustained in an automobile accident","volume":"95","author":"Touloei","year":"2015","journal-title":"Cutis"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1525-1470.2006.00289.x","article-title":"Deep morphea after vaccination in two young children","volume":"23","author":"Torrelo","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3899\/jrheum.080098","article-title":"Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma","volume":"35","author":"Arkachaisri","year":"2008","journal-title":"A Single-Center Study J Rheumatol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/ced.14236","article-title":"Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history","volume":"45","author":"Kaushik","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/idoj.IDOJ_284_19","article-title":"Update on management of Morphea (localized scleroderma) in children","volume":"11","author":"George","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the childhood arthritis and rheumatology research alliance legacy registry","volume":"1","author":"Wu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/bjd.12758","article-title":"Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients","volume":"170","author":"Pequet","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"849","DOI":"10.7326\/0003-4819-104-6-849","article-title":"Linear scleroderma","volume":"104","author":"Falanga","year":"1986","journal-title":"Ann Intern Med"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/pde.12001","article-title":"A significant proportion of children with morphea en coup de sabre and parry-Romberg syndrome have neuroimaging findings","volume":"29","author":"Chiu","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00512-6","article-title":"Magnetic resonance imaging findings in children with parry-Romberg syndrome and en coup de sabre","volume":"19","author":"Knights","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jaad.2005.10.020","article-title":"Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients","volume":"54","author":"Sommer","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00431-018-3144-8","article-title":"Development of minimum standards of care for juvenile localized scleroderma","volume":"177","author":"Constantin","year":"2018","journal-title":"Eur J Pediatr"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/rheumatology\/kem120","article-title":"Ultrasonography is a sensitive tool for monitoring localized scleroderma","volume":"46","author":"Li","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/srt.12660","article-title":"An extended high-frequency ultrasound protocol for assessing and quantifying of inflammation and fibrosis in localized scleroderma","volume":"25","author":"Ranosz-Janicka","year":"2019","journal-title":"Skin Res Technol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/acr.20407","article-title":"Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11926-012-0308-9","article-title":"Recent developments in diagnosis and assessment of morphea","volume":"15","author":"Nouri","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jaad.2010.08.027","article-title":"Activity assessment in morphea using color Doppler ultrasound","volume":"65","author":"Wortsman","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/jum.15843","article-title":"Sun sign in the ultrasound diagnosis and activity assessment of Morphea","volume":"41","author":"Salgueiro","year":"2022","journal-title":"J Ultrasound Med"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ajd.13695","article-title":"Dermoscopy, confocal microscopy and optical coherence tomography features of main inflammatory and autoimmune skin diseases: a systematic review","volume":"63","author":"Guida","year":"2022","journal-title":"Australas J Dermatol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1093\/rheumatology\/keab241","article-title":"How reflectance confocal microscopy can be used\u2002in systemic sclerosis skin diagnosis","volume":"60","author":"Mazzilli","year":"2021","journal-title":"Rheumatology"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"e2022048","DOI":"10.5826\/dpc.1202a48","article-title":"Dermoscopic and reflectance confocal microscopic presentations of superficial Morphea on preexisting Atrophoderma of Pasini and Pierini","author":"Song","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamadermatol.2014.2668","article-title":"In vivo high-definition optical coherence tomography","volume":"151","author":"Su","year":"2015","journal-title":"JAMA Dermatol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000506748","article-title":"Reflectance confocal microscopy applied to linear (en coup de sabre) Morphea","volume":"6","author":"Mazzilli","year":"2020","journal-title":"Skin Appendage Disord"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/srt.12619","article-title":"Detecting and quantifying activity\/inflammation in localized scleroderma with thermal imaging","volume":"25","author":"Ranosz-Janicka","year":"2019","journal-title":"Skin Res Technol"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/rheumatology\/41.10.1178","article-title":"Juvenile-onset localized scleroderma activity detection by infrared thermography","volume":"41","author":"Martini","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s13555-016-0141-6","article-title":"Dermoscopy in general dermatology: a practical overview","volume":"6","author":"Errichetti","year":"2016","journal-title":"Dermatol Ther (Heidelb)."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/jcm11030764","article-title":"Usefulness of dermoscopy in localized scleroderma (LoS, Morphea) diagnosis and assessment-monocentric cross-sectional study","volume":"11","author":"Szczepanik-Ku\u0142ak","year":"2022","journal-title":"J Clin Med"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000484947","article-title":"Dermoscopy of Morphea and cutaneous lichen Sclerosus: clinicopathological correlation study and comparative analysis","volume":"233","author":"Errichetti","year":"2017","journal-title":"Dermatology"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.3899\/jrheum.081284","article-title":"The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures","volume":"36","author":"Arkachaisri","year":"2009","journal-title":"J Rheumatol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","article-title":"Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study","volume":"49","author":"Arkachaisri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jaad.2013.02.007","article-title":"The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population","volume":"69","author":"Kelsey","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/archdermatol.2011.305","article-title":"High frequency of genital lichen Sclerosus in a prospective series of 76 patients with Morphea","volume":"148","author":"Lutz","year":"2012","journal-title":"Arch Dermatol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jaad.2012.04.003","article-title":"Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center","volume":"67","author":"Kreuter","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/08998280.2018.1564966","article-title":"Carcinoma en cuirasse","volume":"32","author":"Culver","year":"2019","journal-title":"Baylor Univ Med Center Proc"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/DAD.0b013e3181cb3fdd","article-title":"Postirradiation Morphea","volume":"1","author":"Morganroth","year":"2013","journal-title":"Am J Dermatopathol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/00128071-200910030-00004","article-title":"Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study","volume":"10","author":"Kroft","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0190-9622(98)70077-5","article-title":"Topical calcipotriene for morphea\/linear scleroderma","volume":"39","author":"Cunningham","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1046\/j.1525-1470.2001.018003241.x","article-title":"Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea","volume":"18","author":"Kreuter","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000335560","article-title":"Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study","volume":"223","author":"Pope","year":"2011","journal-title":"Dermatology"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2310\/7750.2014.14072","article-title":"Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial","volume":"19","author":"Dytoc","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1111\/pde.13647","article-title":"Remission of seizures with immunosuppressive therapy in parry-Romberg syndrome and en coup de sabre linear scleroderma: case report and brief review of the literature","volume":"35","author":"Anderson","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12969-018-0295-0","article-title":"Multi-Centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management","volume":"16","author":"Lythgoe","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0022-3476(00)90056-8","article-title":"Methotrexate and corticosteroid therapy for pediatric localized scleroderma","volume":"136","author":"Uziel","year":"2000","journal-title":"J Pediatr"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","article-title":"Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children","volume":"155","author":"Weibel","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.110210","article-title":"Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study","volume":"39","author":"Torok","year":"2012","journal-title":"J Rheumatol"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archderm.141.7.847","article-title":"Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma","volume":"141","author":"Kreuter","year":"2005","journal-title":"Arch Dermatol"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/s0190-9622(98)70079-9","article-title":"Low-dose methotrexate in the treatment of widespread morphea","volume":"39","author":"Seyger","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref142","first-page":"609","article-title":"Treatment of pediatric localized scleroderma with methotrexate","volume":"33","author":"Fitch","year":"2006","journal-title":"J Rheumatol"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jaad.2012.03.036","article-title":"A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)","volume":"67","author":"Zulian","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1365-2133.2011.10535.x","article-title":"Relapse after systemic treatment in paediatric morphoea","volume":"166","author":"Mirsky","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","article-title":"Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients","volume":"130","author":"Joly","year":"1994","journal-title":"Arch Dermatol"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2340\/00015555-2297","article-title":"Use of mycophenolate Mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamadermatol.2020.0035","article-title":"Evaluation of the effectiveness and tolerability of mycophenolate Mofetil and mycophenolic acid for the treatment of Morphea","volume":"156","author":"Arthur","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/rheumatology\/keaa392","article-title":"Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma","volume":"60","author":"Martini","year":"2021","journal-title":"Rheumatology"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/1346-8138.14801","article-title":"Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin a: a case report and review of the published works","volume":"46","author":"Ogawa","year":"2019","journal-title":"J Dermatol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.jaad.2019.01.040","article-title":"Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at Mayo Clinic, 1996-2013","volume":"80","author":"Kumar","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1365-4632.2012.05741.x","article-title":"Eosinophilic fasciitis\/generalized morphea overlap successfully treated with azathioprine","volume":"53","author":"Alonso-Castro","year":"2014","journal-title":"Int J Dermatol"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"e12455","DOI":"10.1111\/dth.12455","article-title":"Retinoic acid for treatment of systemic sclerosis and morphea: a literature review","volume":"30","author":"Thomas","year":"2017","journal-title":"Dermatol Ther"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1684\/ejd.2021.4173","article-title":"Response of recalcitrant generalized morphea to intravenous immunoglobulins (IVIg): three cases and a review of the literature","volume":"31","author":"Kromer","year":"2021","journal-title":"Eur J Dermatol"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1684\/ejd.2013.1929","article-title":"Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis","volume":"23","author":"Chimenti","year":"2013","journal-title":"Eur J Dermatol"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archdermatol.2010.120","article-title":"Treatment of recalcitrant generalized morphea with infliximab","volume":"146","author":"Diab","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1067\/mjd.2000.108369","article-title":"Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma","volume":"43","author":"Hulshof","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archderm.1990.01670290053007","article-title":"D-penicillamine in the treatment of localized scleroderma","volume":"126","author":"Falanga","year":"1990","journal-title":"Arch Dermatol"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0190-9622(97)80221-6","article-title":"Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma","volume":"36","author":"Hunzelmann","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1346-8138.2003.tb00368.x","article-title":"The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis","volume":"30","author":"Yin","year":"2003","journal-title":"J Dermatol"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1365-2133.2007.07802.x","article-title":"Significant downregulation of transforming growth factor-beta signal transducers in human skin following ultraviolet-A1 irradiation","volume":"156","author":"Gambichler","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0781.2004.00080.x","article-title":"Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study","volume":"20","author":"El-Mofty","year":"2004","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s13555-016-0136-3","article-title":"Phototherapy in scleroderma","volume":"6","author":"Hassani","year":"2016","journal-title":"Dermatol Ther (Heidelberg)"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1001\/archderm.1996.03890350014001","article-title":"PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients","volume":"132","author":"Kerscher","year":"1996","journal-title":"Arch Dermatol"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"21258","DOI":"10.5070\/D3201021258","article-title":"Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP)","volume":"20","author":"Pileri","year":"2014","journal-title":"Dermatol Online J"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archdermatol.2008.547","article-title":"Extracorporeal photochemotherapy for generalized deep morphea","volume":"145","author":"Neustadter","year":"2009","journal-title":"Arch Dermatol"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1468-3083.2007.02403.x","article-title":"Successful therapy of a patient with therapy recalcitrant generalized bullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil","volume":"22","author":"Schlaak","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jaad.2013.10.018","article-title":"Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study","volume":"70","author":"Vasquez","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1034\/j.1600-0781.2000.d01-1.x","article-title":"Low-dose broad-band UVA in morphea using a new method for evaluation","volume":"16","author":"El-Mofty","year":"2000","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/1523-1747.ep12522855","article-title":"The carcinogenic effect of UVA irradiation","volume":"81","author":"Staberg","year":"1983","journal-title":"J Invest Dermatol"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2133.2010.09746.x","article-title":"There are no \u201csafe exposure limits\u201d for phototherapy","volume":"163","author":"Dawe","year":"2010","journal-title":"Br J Dermatol"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.semarthrit.2018.03.003","article-title":"Comparing ultraviolet light a photo (chemo) therapy with methotrexate protocol in childhood localized scleroderma: evidence from systematic review and meta-analysis approach","volume":"48","author":"Marrani","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.3390\/jcm10153409","article-title":"Laser therapy for the treatment of Morphea: a systematic review of literature","volume":"10","author":"Szczepanik-Ku\u0142ak","year":"2021","journal-title":"J Clin Med"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s10103-016-2041-5","article-title":"Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study","volume":"31","author":"Shalaby","year":"2016","journal-title":"Lasers Med Sci"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/pde.13336","article-title":"Orthopedic complications of linear morphea: implications for early interdisciplinary care","volume":"35","author":"Schoch","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.3899\/jrheum.100062","article-title":"En coup de sabre scleroderma and parry-Romberg syndrome in adolescents: surgical options and patient-related outcomes","volume":"37","author":"Palmero","year":"2010","journal-title":"J Rheumatol"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1097\/PRS.0000000000006291","article-title":"Fat grafting for the treatment of scleroderma","volume":"144","author":"Strong","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/PRS.0000000000004386","article-title":"Supportive use of adipose-derived stem cells in cell-assisted Lipotransfer for localized scleroderma","volume":"141","author":"Chen","year":"2018","journal-title":"Plast Reconstr Surg"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"e3373","DOI":"10.1097\/GOX.0000000000003373","article-title":"Fat grafting subjectively improves facial skin elasticity and hand function of scleroderma patients","volume":"9","author":"Strong","year":"2021","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/ijd.12387","article-title":"Imatinib: a novel treatment approach for generalized morphea","volume":"53","author":"Coelho-Macias","year":"2014","journal-title":"Int J Dermatol"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/dth.12248","article-title":"Imatinib treatment of therapy resistant generalized deep morphea","volume":"28","author":"Alc\u00e1ntara-Reifs","year":"2015","journal-title":"Dermatol Ther"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/j.jaad.2010.02.030","article-title":"Imatinib treatment of generalized localized scleroderma (morphea)","volume":"63","author":"Moinzadeh","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/1523-1747.ep12345771","article-title":"Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders","volume":"106","author":"Igarashi","year":"1996","journal-title":"J Invest Dermatol"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI12020","article-title":"Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients","volume":"108","author":"Stratton","year":"2001","journal-title":"J Clin Invest"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/biomedicines10020318","article-title":"Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: why IL-6?","volume":"10","author":"Cardoneanu","year":"2022","journal-title":"Biomedicine"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1365-2133.2006.07391.x","article-title":"Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma","volume":"155","author":"Kreuter","year":"2006","journal-title":"Br J Dermatol"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of Pansclerotic Morphea treated with tocilizumab","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"ref194","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"106","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with Morphea","volume":"140","author":"Damsky","year":"2020","journal-title":"J Invest Dermatol"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1007\/s10067-020-05118-z","article-title":"Full histological and clinical regression of morphea with tofacitinib","volume":"39","author":"Scheinberg","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00296-019-04269-w","article-title":"Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review","volume":"39","author":"Soh","year":"2019","journal-title":"Rheumatol Int"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","article-title":"Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis","volume":"75","author":"Ponsoye","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausb\u00f8l-Gr\u00f8n","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2340\/00015555-2878","article-title":"Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series","volume":"98","author":"Fage","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/pde.12279","article-title":"Pansclerotic morphea with features of eosinophilic fasciitis: distinct entities or part of a continuum?","volume":"31","author":"Odhav","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"ref207","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1546-0096-9-S1-P77","article-title":"Autologous stem cell transplantation in two children with disabling pansclerotic morphea","volume":"9","author":"Moll","year":"2011","journal-title":"Pediatr Rheumatol"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/bjd.12606","article-title":"Short- and long-term outcome of linear morphoea in children","volume":"169","author":"Piram","year":"2013","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1108623\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T05:04:57Z","timestamp":1676264697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1108623\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":208,"alternative-id":["10.3389\/fmed.2023.1108623"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1108623","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"1108623"}}